Annual Report for Financial Year 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dipna Pharmachem Limited has submitted its 14th Annual Report for FY 2024-25 along with the AGM notice. The 14th AGM is scheduled for Saturday, 30th August 2025 at 4:00 PM through video conferencing. The company's turnover for FY 2024-25 stood at Rs. 12,491.71 lakhs. Shareholders will be asked to approve material related party transactions worth up to Rs. 100 crores each with three related entities — Dhara Pharmachem Private Limited, Dipan Pharmachem Private Limited, and Cedac Medicorp. Other items include re-appointment of Mr. Nirav Soni (rotational director), appointment of Mr. Parin Bhavsar as Independent Director for 5 years (effective May 3, 2025), and a marginal increase in authorised share capital from Rs. 25 crore to Rs. 25.5 crore.
This is primarily a routine regulatory filing, but the proposed material RPTs of up to Rs. 100 crore each with three related parties are significant — shareholders should review the rationale and arm's-length nature of these transactions before voting. The small authorised capital hike (2%) suggests a possible minor fundraising plan ahead.